Vinblastine sulphate

Researchers from Eli Lilly pharmaceuticals, (a company founded in 1876 by Colonel Eli Lilly veteran of the US Civil War), undertook further intensive phytochemical studies and characterized 60 alkaloids, of which a group of 20 binary indole alkaloids—including vincristine and vinblastine. Vinblastine sulphate (Velbe ) inhibits the polymerization of tubulin and is used to treat generalized Hodgkin s disease and chorionepithelioma, whereas vincristine sulphate (Oncovin ) is used to treat leukemia in children. 

Vinblastine Sulphate Zorbax C8 Methanol 1.5% w/v soln. of diethylamine adjusted to pH 7.5 with o-phosphoric acid Acetonitrile (50 38 12)/1.0ml min-1 (1) to (5) kept in ice before use UV-detector 262 nm Based on the declared content ofCAN/), H2S04 in EPCRS. 

Nickerson, S. C., Smith, J. J. and Keenan, T. W. 1980B. Ultrastructural and biochemical response of rat mammary epithelial cells to vinblastine sulphate. Eur. J. Cell Biol. 23, 115-121. 

Infra-red Spectrum. Principal peaks at wavenumbers 1227,1136, 1111, 1724, 1176, 1613 (vinblastine sulphate, KBr disk). 

Dose. Initially 100 xg/kg of vinblastine sulphate weekly, by intravenous injection. 

Codeine Hydrochloride Dequalinium Acetate Fluorometholone Hexamethonium Bromide Riboflavine Stilbazium Iodide Mianserin Hydrochloride Tacrine Hydrochloride Diclofenac Sodium Vinblastine Sulphate Cyclizine Hydrochloride Amiloride Hydrochloride Protoveratrine B Meclofenamate Sodium 5-Methyltryptamine Hydrochloride Dicoumarol Mebendazole Pipradrol Hydrochloride Carbenoxolone Flucytosine Phanquone Phenytoin... 

Vibramycin-D, 575 Vibra-Tabs, 575 Vibraveineuse, 575 Vibravenos, 575 Vibrocil, 550, 893 Vicilan, 1061 Vidopen, 351 Vidue, 586 Vigantolo, 586 Vigon-DC, 531 Vikasolum, 729 Vikonon, 1067 Villescon, 931 Viloxazine, 1061 Viloxazine hydrochloride, 1061 Vimicon, 506 Vinbarbital, 1062 Vinbarbitone, 1062 Vinblastine, 1063 Vinblastine sulphate, 1063 Vinca rosea, 1063 Vincaleucoblastine, 1063 Vincaleukoblastine, 1063 Vinclozolin, 85 Vincristine, 1063 Vincristine sulphate, 1063... 

Black, J., Buechter, D.D., and Thurston, D.F. (1988) Stability of vinblastine sulphate when exposed to light, Drug Intell. Clin. Pharm., 22, 634-635. 

Vinblastine sulphate. Mayne Fliarma pic. Summary of M oduct characteristics, January 2003. 

Structure-activity studies have led to the development of vinglycinate sulphate (Xlf). Administration of the drug to 31 patients with malignant diseases has resulted in beneficial response with Hodgkin s disease, lymphosarcoma, bronchogenic carcinoma, and chondrosarcoma There is a lack of cross-resistance between vinglycinate and vinblastine or vincristine, and the dose required is approximately ten times that of vinblastine. Leukopenia is the dose limiting factor [83]. 

---